
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HG-CT-1
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Made Scientific
Deal Size : Undisclosed
Deal Type : Partnership
Made Scientific and Hemogenyx Announce Technology Transfer and Manufacturing Partnership
Details : The partnership aims to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 08, 2025
Lead Product(s) : HG-CT-1
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Made Scientific
Deal Size : Undisclosed
Deal Type : Partnership

Hemogenyx raises £570,000 and Director's Dealing
Details : The net proceeds will be used for Phase I clinical trial of the Company's Chimeric Antigen Receptor T-cell therapy, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia.
Product Name : HG-CT-1
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HG-CT-1,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Details : HG-CT-1 is a proprietary anti-FLT3 CAR-T cell therapy, being investigated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : HG-CT-1,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1
Details : HG-CT-1, is a CAR-T cell therapy, which is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 24, 2025

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/refractory AML
Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 22, 2025

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated for the treatment of r/r acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 22, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Prevail Partners
Deal Size : $0.3 million
Deal Type : Financing
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Details : THe proceeds will be used in clinical services and technologies for the Company's upcoming Phase I of an anti-FLT3 CAR-T cells in pediatric subjects with R/R AML and a subset of ALL.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Prevail Partners
Deal Size : $0.3 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanized monoclonal antibody. It is being evaluated in preclinical studies for the treatment of r/r acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 02, 2024
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated in preclinical studies for the treatment of acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
Details : Human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin Lymphoma derived cells with high efficiency in vitro.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
